CO.DON GmbH partners in EU-Funded Project to Advance 3D Bioprinting for Tissue Regeneration
5.2.2025 15:00:00 CET | news aktuell GmbH | Press Release
Teltow, 05. February 2025 – The EU-funded micro2MACRO (m2M) project, launched in December 2024, aims to advance tissue regeneration through an innovative bioprinting platform.
m2M focuses on precisely patterning cell aggregates and microtissues into stable, customizable grafts that remodel into functional tissues after implantation. The project unites leading academic institutions, research centers, and companies to develop scalable, personalized grafts for tissue repair.
"We are proud to be a partner in the m2M project and believe in its potential to significantly advance the development of therapies for the regeneration of tissue. We are happy to contribute and share our more than 30 years of experience in the field of regenerative medicine as well as our regulatory expertise as the holder of an EU approved cell-based therapy for cartilage repair" explained Dr. Giulietta Roël, Executive Director of CO.DON GmbH.
Beyond technical development, m2M will foster knowledge exchange and workshops to enhance researchers' and healthcare professionals' skills across Europe.
Contacts
Matthias MeißnerDirector Corporate CommunicationsCO.DON
Tel:+49 (0)341 99190 330pr@codon.deLinks
About us
CO.DON develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells. More than 20,000 patients have already been treated with CO.DON's method. In January 2023, CO.DON GmbH was acquired by ReLive Biotechnologies, a global company headquartered in the US.
Managing Director: Dr. Ying Zhou
Further information is available at www.codon.de | www.relivebio.com
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
fiskaltrust Launches Portugal’s only Certified Fiscalisation Middleware and CashBox10.3.2026 08:30:00 CET | Press Release
Integration Partners and Commercial Partners can now access the Portuguese market through fiskaltrust's POS System API, covering full AT (Autoridade Tributária e Aduaneira) compliance. SALZBURG. fiskaltrust.eu, the European fintech company delivering Compliance-as-a-Service for point-of-sale systems, announced the launch of the only fully certified fiscalisation Middleware and CashBox for Portugal. Through a single integration to fiskaltrust's POS System API, Integration Partners can now access the Portuguese market with full compliance coverage without building or maintaining any local fiscal infrastructure themselves. fiskaltrust's certified Middleware and CashBox for Portugal handles the full compliance stack through the POS System API, the same interface used by Integration Partners across Austria, Germany, France, Italy, Spain, and Greece. Payments Integration Through Viva.com Every payment generates a fiscal event and fiskaltrust aligns payment and receipt data in real time. For
WELEDA x Stella McCartney: Paris Fashion Week / Skin Food: 100 years of loving skin9.3.2026 13:30:04 CET | Press Release
Arlesheim, 09th March 2026. During this season’s Paris Fashion Week, WELEDA is backstage at the Stella McCartney show ensuring radiant skin: make-up artists draw specifically on the trusted nurturing power of the WELEDA Skin Food range to prep and prime the runway models’ skin perfectly for make-up and create a natural glow.
Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm5.3.2026 08:40:44 CET | Press Release
Aachen, Germany & Yeoju, South Korea, 5 March 2026 – Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will have the exclusive South Korean rights to Qutenza®, a topical, non-systemic, non-opioid patch treatment. In Europe, the product is indicated for the management of peripheral neuropathic pain. Under the agreement, BCWP will be responsible for obtaining marketing authorisation for Qutenza® in South Korea. Upon approval, the company will market and distribute the product. Grünenthal will receive an upfront payment in addition to regulatory and sales-related milestone payments. “We are executing on a dedicated strategy to bring Qutenza® into the Asia-Pacific region to facilitate greater access to non-opioid treatment opt
Compax MVNE continues to support Airalo’s eSIM platform2.3.2026 13:38:56 CET | Press Release
Vienna, March 2nd, 2026: Compax, a leading solution provider in the MVNO and telco space, will continue to support Airalo, the world’s first and largest eSIM platform.
Grünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands2.3.2026 10:07:51 CET | Press Release
Grünenthal acquired Kyowa Kirin International’s 49% stake in ‘Grünenthal Meds’, a joint venture formed in 2023 to market the established medicines portfolio from Kyowa Kirin International. Through this acquisition, Grünenthal assumes the sole responsibility of a portfolio comprising 12 brands across six therapeutic areas and >60 markets.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom